PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW

Background: Pharmacovigilance (PV) detects, assesses and prevents adverse drug reactions (ADRs) and other medicine-related problems. East African countries have built national PV systems, but underreporting and the weak visibility of links between safety information and regulatory decisions persist. Objectives: To map evidence on PV systems and regulatory action in East Africa with emphasis on Tanzania; to quantify key PV outcomes among health professionals; to identify factors associated with ADR reporting; and to describe how safety information is translated into regulatory action. Methods: Rapid scoping review following the Arksey and O’Malley framework, Joanna Briggs Institute guidance and PRISMA-ScR reporting, with a conditional quantitative synthesis. Targeted searches of web-indexed biomedical literature, repositories and regulatory and media sources were run in October 2026. Results: Twenty-five sources were charted: 17 research sources (Tanzania, Uganda, Kenya, Ethiopia, Rwanda and two multi-country studies) and eight regulatory, programme and media reports. In 2017/18, spontaneous reporting was 4.1 reports per million inhabitants in mainland Tanzania, 6.7 in Ethiopia and 35.0 in Kenya, and no more than 1% of facilities submitted reports. Nine surveys of health professionals (n=3,091) gave a pooled ADR-reporting proportion of 30.3% (95% CI 19.1–44.4%; I²=97.9%; 95% prediction interval 4.3–81.0%). Conclusions: PV structures have advanced and reporting can be raised sharply by training and stimulated reporting, but low and uneven reporting, training gaps and limited visibility of locally triggered regulatory action constrain medicine safety. Peer Review History: Received 25 July 2026; Reviewed 3 September 2026; Accepted 8 October; Available online 15 November 2026 Academic Editor: Dr. Jennifer Audu-Peter, University of Jos, Nigeria, [email protected] Reviewers: Dr. Noha El Baghdady, MTI University, Cairo, Egypt, [email protected] Dr. Mayada M. El-Azab, Phytochemistry Unit, Department of Medicinal and Aromatic Plants, Desert Research Center, Cairo, Egypt. [email protected]

Authors

Publication Details

Journal
Universal Journal of Pharmaceutical Research
Published
2026-11-15
DOI
https://doi.org/10.22270/ujpr.v11i5.1671
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW

Kennedy John Ndetico, Lambert Philipo Barugahale, Lewis Mwombeki, Sechelela Vincent Lemanya
Universal Journal of Pharmaceutical Research
Pharmacovigilance and Adverse Drug Reactions
article

PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW

Kennedy John Ndetico, Lambert Philipo Barugahale, Lewis Mwombeki, Sechelela Vincent Lemanya
article en

Abstract

Background: Pharmacovigilance (PV) detects, assesses and prevents adverse drug reactions (ADRs) and other medicine-related problems. East African countries have built national PV systems, but underreporting and the weak visibility of links between safety information and regulatory decisions persist. Objectives: To map evidence on PV systems and regulatory action in East Africa with emphasis on Tanzania; to quantify key PV outcomes among health professionals; to identify factors associated with ADR reporting; and to describe how safety information is translated into regulatory action. Methods: Rapid scoping review following the Arksey and O’Malley framework, Joanna Briggs Institute guidance and PRISMA-ScR reporting, with a conditional quantitative synthesis. Targeted searches of web-indexed biomedical literature, repositories and regulatory and media sources were run in October 2026. Results: Twenty-five sources were charted: 17 research sources (Tanzania, Uganda, Kenya, Ethiopia, Rwanda and two multi-country studies) and eight regulatory, programme and media reports. In 2017/18, spontaneous reporting was 4.1 reports per million inhabitants in mainland Tanzania, 6.7 in Ethiopia and 35.0 in Kenya, and no more than 1% of facilities submitted reports. Nine surveys of health professionals (n=3,091) gave a pooled ADR-reporting proportion of 30.3% (95% CI 19.1–44.4%; I²=97.9%; 95% prediction interval 4.3–81.0%). Conclusions: PV structures have advanced and reporting can be raised sharply by training and stimulated reporting, but low and uneven reporting, training gaps and limited visibility of locally triggered regulatory action constrain medicine safety. Peer Review History: Received 25 July 2026; Reviewed 3 September 2026; Accepted 8 October; Available online 15 November 2026 Academic Editor: Dr. Jennifer Audu-Peter, University of Jos, Nigeria, [email protected] Reviewers: Dr. Noha El Baghdady, MTI University, Cairo, Egypt, [email protected] Dr. Mayada M. El-Azab, Phytochemistry Unit, Department of Medicinal and Aromatic Plants, Desert Research Center, Cairo, Egypt. [email protected]

Universal Journal of Pharmaceutical Research
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon